References
- Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang L. Prognostic significance of systematic lymphadenectomy in patients with optimally debulked advanced ovarian cancer: a meta-analysis. Front Oncol. 2020;10:86.
- Aletti GD, Dowdy S, Podratz KC, Cliby WA. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol. 2006;195(6):1862–1868. doi:https://doi.org/10.1016/j.ajog.2006.06.068.
- Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007;96(12):1817–1822. doi:https://doi.org/10.1038/sj.bjc.6603803.
- du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28(10):1733–1739. doi:https://doi.org/10.1200/JCO.2009.25.3617.
- Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95(6):699–704. doi:https://doi.org/10.1038/sj.bjc.6603323.
- Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–832. doi:https://doi.org/10.1056/NEJMoa1808424.
- Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97(8):560–566. doi:https://doi.org/10.1093/jnci/dji102.
- Cheng A, Lang J. Survival analysis of lymph node resection in ovarian cancer: a population-based study. Front Oncol. 2020;10:355.
- Harter P, Heitz F, Ataseven B, Schneider S, Baert T, Prader S, et al. How to manage lymph nodes in ovarian cancer. Cancer. 2019;125(Suppl 24):4573–4577. doi:https://doi.org/10.1002/cncr.32514.
- Eggemann H, Ignatov T, Kaiser K, Burger E, Costa SD, Ignatov A. Survival advantage of lymphadenectomy in endometrial cancer. J Cancer Res Clin Oncol. 2016;142(5):1051–1060. doi:https://doi.org/10.1007/s00432-015-2109-9.
- Ignatov T, Eggemann H, Costa SD, Ortmann O, Ignatov A. Endometrial cancer subtypes are associated with different patterns of recurrence. J Cancer Res Clin Oncol. 2018;144(10):2011–2017. doi:https://doi.org/10.1007/s00432-018-2711-8.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi:https://doi.org/10.1016/S0140-6736(07)61602-X.
- Ignatov T, Eggemann H, Burger E, Costa SD, Ignatov A. Management of small T1a/b breast cancer by tumor subtype. Breast Cancer Res Treat. 2017;163(1):111–118. doi:https://doi.org/10.1007/s10549-017-4168-x.
- Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610–614. doi:https://doi.org/10.1016/j.ygyno.2011.09.013.
- Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122(3):536–540. doi:https://doi.org/10.1016/j.ygyno.2011.05.001.
- Trimbos JB, , Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95(2):113–125. doi:https://doi.org/10.1093/jnci/95.2.113.
- Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J Clin Oncol. 2015;45(1):49–60. doi:https://doi.org/10.1093/jjco/hyu175.
- Heitz F, Harter P, Ataseven B, Heikaus S, Schneider S, Prader S, et al. Stage- and histologic subtype-dependent frequency of lymph node metastases in patients with epithelial ovarian cancer undergoing systematic pelvic and paraaortic lymphadenectomy. Ann Surg Oncol. 2018;25(7):2053–2059. doi:https://doi.org/10.1245/s10434-018-6412-y.
- Nasioudis D, Mastroyannis SA, Ko EM, Latif NA. Does tumor grade influence the rate of lymph node metastasis in apparent early stage ovarian cancer? Arch Gynecol Obstet. 2018;298(1):179–182. doi:https://doi.org/10.1007/s00404-018-4789-2.
- Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010;102(13):982–987. doi:https://doi.org/10.1093/jnci/djq149.
- Signorelli M, Fruscio R, Ceppi L, Dell'anna T, Vitobello D, Chiappa V, et al. The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy. Gynecol Oncol. 2014;132(2):312–315. doi:https://doi.org/10.1016/j.ygyno.2014.01.001.
- Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015;2015(12): CD004706.